Telomir Pharmaceuticals, Inc.
TELO
$1.29
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -92.30% | 171.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -77.39% | 131.74% | |||
| Operating Income | 77.39% | -131.74% | |||
| Income Before Tax | 78.26% | -132.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 78.26% | -132.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 78.26% | -132.59% | |||
| EBIT | 77.39% | -131.74% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 79.87% | -130.74% | |||
| Normalized Basic EPS | 79.83% | -130.57% | |||
| EPS Diluted | 79.87% | -130.74% | |||
| Normalized Diluted EPS | 79.83% | -130.57% | |||
| Average Basic Shares Outstanding | 7.96% | 0.83% | |||
| Average Diluted Shares Outstanding | 7.96% | 0.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||